Urinary nitrate excretion is increased in patients with rheumatoid arthritis and reduced by prednisolone

OBJECTIVES--To determine daily production of nitric oxide (NO) measured as urinary nitrate excretion, and the effect of prednisolone in patients with rheumatoid arthritis (RA). METHODS--Twenty four hour urinary nitrate was measured by gas chromatography in 10 patients with RA, before and two to four...

Full description

Saved in:
Bibliographic Details
Published in:Annals of the rheumatic diseases Vol. 54; no. 10; pp. 820 - 824
Main Authors: Stichtenoth, D O, Fauler, J, Zeidler, H, Frölich, J C
Format: Journal Article
Language:English
Published: London BMJ Publishing Group Ltd and European League Against Rheumatism 01-10-1995
BMJ
BMJ Publishing Group LTD
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:OBJECTIVES--To determine daily production of nitric oxide (NO) measured as urinary nitrate excretion, and the effect of prednisolone in patients with rheumatoid arthritis (RA). METHODS--Twenty four hour urinary nitrate was measured by gas chromatography in 10 patients with RA, before and two to four weeks after commencement of prednisolone 0.5 mg/kg body weight, and in 18 healthy controls. RESULTS--Before the start of prednisolone treatment the urinary nitrate excretion in patients with RA was 2.7-fold greater (p < 0.001) than that in healthy volunteers. After prednisolone it decreased significantly, by 28%, at which time inflammatory activity (as indicated by C reactive protein, erythrocyte sedimentation rate, joint count, and early morning stiffness) was also reduced considerably. Despite this decrease, the urinary nitrate excretion in patients with RA remained twice that in the control group (p < 0.05). CONCLUSIONS--Our data suggest that the endogenous production of NO is enhanced in patients with RA. Furthermore, the results indicate that, in parallel with suppression of inflammation, this increased NO synthesis could be reduced by prednisolone treatment.
Bibliography:istex:3D4F5B741F017A20D268CA0965CF56DF1DCC1F00
href:annrheumdis-54-820.pdf
local:annrheumdis;54/10/820
PMID:7492221
ark:/67375/NVC-2QB825G6-X
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0003-4967
1468-2060
DOI:10.1136/ard.54.10.820